1 January 2023 in Brazilian Journal of Medical and Biological Research
The impact of linseed oil as a lipid source on liver disease induced by a high-carbohydrate diet (HCD) was evaluated. Adult male Swiss mice received an HCD containing carbohydrates (72.1%), proteins (14.2%), and lipids (4.0%). The Control HCD group (HCD-C) received an HCD containing lard (3.6%) and soybean oil (0.4%) as lipid sources. The L10 and L100 groups received an HCD with 10 and 100% linseed oil as lipid sources, respectively. A group of mice were euthanized before receiving the diets (day 0) and the remaining groups after 56 days of receiving the diets (HCD-C, L10, and L-100 groups). Morphological and histopathological analyses, as well as collagen deposition were evaluated. Perivenous hepatocytes (PVH) of the HCD-C group were larger (P<0.05) than periportal hepatocytes (PPH) in the median lobe (ML) and left lobe (LL). There was a greater (P<0.05) deposition of type I collagen in PPH (vs PVH) and in the ML (vs LL). The ML exhibited a higher proportion of apoptotic bodies, inflammatory infiltrate, and hepatocellular ballooning. All these alterations (hepatocyte size, deposition of type I collagen, apoptotic bodies, inflammatory infiltrate, and hepatocellular ballooning) induced by HCD were prevented or attenuated in L10 and L100 groups. Another indicator of the beneficial effects of linseed oil was the lower (P<0.05) number of binucleated hepatocytes (HCD-C vs L10 or L100 group). In general, the L100 group had greater effects than the L10 group. In conclusion, linseed oil impedes or reduces the liver injury progression induced by an HCD.
1 January 2026 in Brazilian Journal of Medical and Biological Research
We investigated the potential of the association between microencapsulated quercetin (MEQ) and the probiotic Bifidobacterium animalis in 1,2-dimethylhydrazine (DMH)-induced colorectal cancer (CRC) in Wistar rats with a focus on hepatic alterations and liver lobar heterogeneity. The rats were divided into 5 groups: control (C), CRC (CR), CRC treated with MEQ (CRQ), CRC treated with the probiotic (CRP), and CRC treated with MEQ + probiotic (CRQP). DMH (40 mg/kg) was administered intraperitoneally twice weekly for two weeks. MEQ (10 mg/kg) and the probiotic (5×107 colony forming units) were administered by gavage for 13 weeks. The liver was evaluated by histomorphometry and redox state analyses. CRC was confirmed by aberrant crypt foci in 100% of the DMH animals. The CR group showed increased hepatosomatic index (HSI) and lobe-specific cellular hypertrophy. The treatments reduced the HSI, with the association MEQ + probiotic being the most effective in preventing the physiopathological process associated with CRC. Deep learning-assisted cell quantification revealed a reduction of mononucleated hepatocytes in the CR group, a condition abolished by all treatments. DMH induced asymmetric glycogen accumulation and extracellular matrix remodeling, which were modulated by MEQ and the probiotic. Redox state analysis showed thiol depletion in the caudate lobe, where the quadrate lobe underwent lipid peroxidation and catalase inhibition. The treatments reestablished thiol levels and catalase activity in both lobes, thereby confirming antioxidant and hepatoprotective properties. In conclusion, the association of MEQ and probiotic exhibited lobar heterogeneity in attenuating hepatic damage reinforcing the importance of liver lobar analysis in the therapeutic evaluation of carcinogenesis.
16 April 2022 in Arquivos do Mudi
Infecções por Staphylococcus aureus resistentes a meticilina (MRSA) são frequentes e possuem elevados níveis de mortalidade, principalmente em pacientes hospitalizados. A vancomicina está entre as drogas de escolha para o tratamento de tais infecções. Tendo em vista as limitações terapêuticas e o surgimento de resistência faz-se necessário estratégias para otimizar a farmacocinética e a farmacodinâmica da vancomicina. O objetivo deste trabalho foi estudar estratégias terapêuticas para otimizar o tratamento com vancomicina. A AUC/MIC>400 é uma medida proposta para otimizar a efetividade do tratamento do MRSA, no entanto esta estratégia não é rotina na prática clínica em virtude das limitações técnicas. A concentração mínima entre 16-20 mg/L e a máxima de 80 mg/L é geralmente padronizada para garantir a eficácia do tratamento e minimizar os efeitos adversos. Além disso, a fim de reduzir a nefrotoxicidade causada pela vancomicina propõem-se o regime de infusão continua que favorece a eficácia do tratamento.